MedDRA preferred term · infection inside the eye

Endophthalmitis: adverse event reports recording this term

5,912 reports to FDA record it, 2004–2026; 0% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

5,912
reports recording the term: 0% of all reports; 338
reports, 12 months to June 2026: 431 in the 12 months before; 97.5%
marked serious by the reporter: 57.4% across all reports; 2.1%
record death among outcomes, as reported: 9.1% across all reports

"Endophthalmitis" (in plain words, infection inside the eye) is a MedDRA preferred term recorded in 5,912 adverse event reports received by FDA, 0% of the database, from January 2004 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

338 reports recorded it in the 12 months to June 2026, down 22% from 431 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 97.5% are marked serious, 2.1% include death among the outcomes and 21.8% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Eylea, Avastin and Bevacizumab. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Eylea	Vascular endothelial growth factor inhibitor	1,210	4.7%
Avastin	Vascular endothelial growth factor inhibitor	648	1.1%
Bevacizumab	Vascular endothelial growth factor inhibitor	553	1%
Lucentis	Vascular endothelial growth factor inhibitor	519	2.5%
Ozurdex	Corticosteroid	277	11.1%
Bss	Osmotic laxative	263	25.1%
Vabysmo	—	244	3.4%
Prednisone	Corticosteroid	208	0.1%
Tacrolimus	Calcineurin inhibitor immunosuppressant	206	0.2%
Ranibizumab	Vascular endothelial growth factor inhibitor	183	3.8%
Dexamethasone	Corticosteroid	172	0.1%
Mycophenolate mofetil	Antimetabolite immunosuppressant	172	0.2%
Voriconazole	Azole antifungal	124	0.9%
Ceftazidime	Cephalosporin antibacterial	117	3.5%
Prednisolone	Corticosteroid	113	0.1%
Aflibercept	Vascular endothelial growth factor inhibitor	107	3.9%
Bss Plus	—	106	31.3%
Vancomycin	Glycopeptide antibacterial	106	0.3%
Amphotericin b	Lipid-based polyene antifungal	99	1.5%
Betadine	—	86	7.6%
Moxifloxacin	Fluoroquinolone antibacterial	83	0.9%
Prednisolone acetate	Corticosteroid	81	2.2%
Linezolid	Oxazolidinone antibacterial	78	0.4%
Maxidex	Corticosteroid	75	16.4%
Eylea Hd	Vascular endothelial growth factor inhibitor	73	6.7%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Vascular endothelial growth factor inhibitor	3,336	1.9%	1.8%
Corticosteroid	1,128	0.1%	0%
Fluoroquinolone antibacterial	282	0.3%	0.6%
Osmotic laxative	263	0.2%	0%
Calcineurin inhibitor immunosuppressant	233	0.1%	0%
Antimetabolite immunosuppressant	194	0.2%	0.1%
Cephalosporin antibacterial	179	0.3%	0%
Azole antifungal	158	0.2%	0%
Glycopeptide antibacterial	143	0.4%	0.5%
Aminoglycoside antibacterial	124	0.3%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.1%5

2 to 110.2%12

12 to 170.3%16

18 to 444.8%286

45 to 6413.8%815

65 to 7414.7%868

75 and over20%1,182

Age not given46.1%2,728

Patient sex

Female33.4%1,972

Male31.6%1,869

Not given35%2,071

Grey bar: all 20,646,523 reports in the database. 48.5% of these reports give the United States as the country.

Questions about "Endophthalmitis"

What does "Endophthalmitis" mean in an adverse event report?

In plain language: infection inside the eye. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record endophthalmitis?

5,912 reports through June 2026 (0% of all reports), 338 of them in the latest 12 months.

Which drugs appear most often in these reports?

Eylea (1,210), Avastin (648), Bevacizumab (553), Lucentis (519) and Ozurdex (277). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.